SEI Investments
RPRX icon

SEI Investments’s Royalty Pharma RPRX Stock Holding History

SEI Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Sell
263,736
-115,990
-31% -$6.04M 0.01% 937
2026
Q1 		$18.2M Sell
379,726
-99,990
-21% -$4.38M 0.02% 832
2025
Q4 		$18.5M Buy
479,716
+369,949
+337% +$14.1M 0.02% 778
2025
Q3 		$3.87M Buy
109,767
+6,403
+6% +$232K ﹤0.01% 1412
2025
Q2 		$3.72M Sell
103,364
-71,537
-41% -$2.37M ﹤0.01% 1385
2025
Q1 		$5.44M Buy
174,901
+65,344
+60% +$2.07M 0.01% 1229
2024
Q4 		$2.8M Buy
109,557
+40,271
+58% +$1.07M ﹤0.01% 1555
2024
Q3 		$1.96M Buy
69,286
+215
+0.3% +$5.96K ﹤0.01% 1696
2024
Q2 		$1.82M Buy
69,071
+31,055
+82% +$861K ﹤0.01% 1675
2024
Q1 		$1.15M Buy
38,016
+121
+0.3% +$3.57K ﹤0.01% 1827
2023
Q4 		$1.06M Buy
37,895
+4,394
+13% +$121K ﹤0.01% 1858
2023
Q3 		$909K Buy
33,501
+3,873
+13% +$115K ﹤0.01% 1918
2023
Q2 		$911K Buy
29,628
+2,441
+9% +$82.7K ﹤0.01% 1907
2023
Q1 		$979K Buy
27,187
+12,365
+83% +$458K ﹤0.01% 1881
2022
Q4 		$586K Sell
14,822
-9,456
-39% -$395K ﹤0.01% 1948
2022
Q3 		$974K Buy
24,278
+7,805
+47% +$333K ﹤0.01% 1808
2022
Q2 		$665K Buy
16,473
+8,081
+96% +$331K ﹤0.01% 1989
2022
Q1 		$281K Buy
8,392
+379
+5% +$14.9K ﹤0.01% 2330
2021
Q4 		$273K Sell
8,013
-3,650
-31% -$142K ﹤0.01% 2363
2021
Q3 		$339K Sell
11,663
-114,755
-91% -$4.46M ﹤0.01% 2267
2021
Q2 		$5.15M Buy
126,418
+33,142
+36% +$1.41M 0.01% 1055
2021
Q1 		$4.13M Buy
93,276
+87,242
+1,446% +$4.14M 0.01% 1118
2020
Q4 		$325K Buy
+6,034
New +$256K ﹤0.01% 2174

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SEI Investments's RPRX Position: Q2 2026 in Review

SEI Investments reduced its Royalty Pharma (RPRX) stake by 31% in Q2 2026, selling an estimated $6.04M and leaving 263,736 shares worth $14.8M. The position accounts for 0.01% of the portfolio, ranked #937.

SEI Investments first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. The position peaked at $18.5M in Q4 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • SEI Investments held 263,736 shares of Royalty Pharma worth $14.8M as of Q2 2026.
  • SEI Investments sold 115,990 Royalty Pharma shares in Q2 2026, an estimated $6.04M.
  • Royalty Pharma made up 0.01% of SEI Investments's portfolio in Q2 2026, its #937 holding.
  • SEI Investments first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • SEI Investments's Royalty Pharma position peaked at $18.5M in Q4 2025.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.